| fullrecord |
[{"key": "dc.contributor.advisor", "value": "Yl\u00e4nne, Jari", "language": null, "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.advisor", "value": "Saarenheimo, Jatta", "language": null, "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.advisor", "value": "Elomaa, Hanna", "language": null, "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.author", "value": "Kivel\u00e4, Essi", "language": "", "element": "contributor", "qualifier": "author", "schema": "dc"}, {"key": "dc.date.accessioned", "value": "2024-06-05T06:18:04Z", "language": null, "element": "date", "qualifier": "accessioned", "schema": "dc"}, {"key": "dc.date.available", "value": "2024-06-05T06:18:04Z", "language": null, "element": "date", "qualifier": "available", "schema": "dc"}, {"key": "dc.date.issued", "value": "2024", "language": null, "element": "date", "qualifier": "issued", "schema": "dc"}, {"key": "dc.identifier.uri", "value": "https://jyx.jyu.fi/handle/123456789/95519", "language": null, "element": "identifier", "qualifier": "uri", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Lung cancer is the most fatal cancer worldwide with non-small cell lung cancer and its subtypes adenocarcinoma and squamous cell carcinoma accounting for approximately 80% of all lung cancer cases. In lung cancer treatment immunotherapies, such as PD-L1 checkpoint inhibitors, are widely in use alongside the conventional cancer treatments surgery, radiation, and chemotherapy to improve treatment outcome and survival rate. Immune cell density and composition are heterogenous between tumors and different tumor sites, and research could help better understand the interactions between host tissue and tumor to reveal possible new targets for immunotherapy, as well as new prognostic biomarkers. Multiplex immunohistochemistry enables the use of several monoclonal antibodies for the same tissue section so that many different types of immune cells and their relations to each other to be investigated for effective biomarker research. In the thesis study different subtypes of T lymphocytes, innate lymphoid cells (ILCs), macrophages, and natural killer (NK) cells were stained using specific monoclonal antibodies to calculate respective cell densities within the central tumor and invasive margin of lung cancer tumors. CD8+ and CD4+ T lymphocytes, ILCs, NK cells and macrophages were phenotyped in QuPath bioimage analysis software, while regulatory T lymphocytes, T helper lymphocyte subtypes Th1, Th2, and Th17, and ILC subtypes ILC1, ILC2, and ILC3 were phenotyped by intensity thresholds. Density calculations for each cell type within the tumor center and invasive margin were made. Together with extensive patient data the effect of Th1, Th2, and Th17 on long-term survival was assessed. Th17 was found to have a statistically significant impact on cancer-specific survival three years post operation in the tumor center, and five years post operation both in the tumor center and invasive margin. The findings are, however, contradictory to most results in literature, and more research needs to be made to specify why such results were obtained.", "language": "en", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Maailmanlaajuisesti keuhkosy\u00f6p\u00e4 on kuolettavin kaikista sy\u00f6vist\u00e4. Ei-pienisoluinen keuhkosy\u00f6p\u00e4 ja sen alatyypit adeno- ja levyepiteelikarsinooma kattavat noin 80 % kaikista keuhkosy\u00f6p\u00e4tapauksista. Immunoterapiaa, kuten PD-L1 inhibiittoreita, k\u00e4ytet\u00e4\u00e4n jo keuhkosy\u00f6v\u00e4n hoidossa yhdess\u00e4 perinteisten hoitomuotojen, kuten leikkauksen, s\u00e4teilyhoidon ja kemoterapian, kanssa, jolloin hoito on tehokkaampaa ja suhteellinen elossaololuku nousee. Immuunisolujen sijainti ja m\u00e4\u00e4r\u00e4 voi vaihdella suuresti kasvaimen eri alueiden ja potilaiden v\u00e4lill\u00e4. N\u00e4iden eroavaisuuksien ja keskin\u00e4isen vuorovaikutuksen ymm\u00e4rt\u00e4minen auttaa l\u00f6yt\u00e4m\u00e4\u00e4n ja tunnistamaan uusia immunoterapiakohteita sek\u00e4 prognostisia biomarkkereita. Useiden eri immuunisolujen ja niiden keskin\u00e4isten suhteiden tutkiminen on mahdollista syklisen multiplex immunohistokemiallisen v\u00e4rj\u00e4ysmenetelm\u00e4n avulla. Syklinen v\u00e4rj\u00e4ysmenetelm\u00e4 mahdollistaa jokaisen solun tunnistamisen ja luokittelun usean markkerin avulla samanaikaisesti. Lis\u00e4ksi solujen v\u00e4lisi\u00e4 spatiaalisia suhteita ja solutiheyksi\u00e4 voidaan mitata ja laskea tietokoneavusteisesti. Tutkimuksessa tutkittiin T lymfosyyttej\u00e4, luonnollisia lymfosyyttej\u00e4 (engl. innate lymphoid cell, ILC), makrofageja sek\u00e4 luontaisia tappajasoluja (engl. natural killer cells, NK cells), jotka v\u00e4rj\u00e4ttiin spesifeill\u00e4 monoklonaalisilla vasta-aineilla, ja niiden tiheydet keuhkokasvaimen keskell\u00e4 ja invaasiorintamalla laskettiin. CD8+ ja CD4+ lymfosyytit, ILC ja NK solut sek\u00e4 makrofagit tunnistettiin QuPath kuva-analyysiohjelmistolla. Solut luokiteltiin alatyyppeihin (s\u00e4\u00e4telev\u00e4t T lymfosyytit, T-auttajasolujen alatyypit Th1, Th2 ja Th17, sek\u00e4 ILC1, ILC2 ja ILC3 solut) intensiteettiraja-arvojen perusteella. Eri T lymfosyyttityyppien, ILC solujen, makrofagien, ja NK solujen solutiheydet kasvaimen keskustassa ja invaasiorintamassa laskettiin. Th1, Th2 ja Th17 solujen vaikutusta potilaiden pitk\u00e4aikaiseen selviytymiseen tutkittiin. Tilastollisesti merkitt\u00e4v\u00e4 vaikutus sy\u00f6p\u00e4spesifiin selviytymiseen kolme vuotta leikkauksen j\u00e4lkeen saatiin Th17 solujen runsaasta esiintymisest\u00e4 kasvaimen keskustassa, ja viisi vuotta leikkauksen j\u00e4lkeen sek\u00e4 kasvaimen keskustassa ett\u00e4 invaasiorintamalla. Tulokset ovat ristiriidassa useimpien julkaisujen kanssa, joten lis\u00e4\u00e4 tutkimusta tarvitaan tulosten selitt\u00e4miseksi.", "language": "fi", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Submitted by Paivi Vuorio (paelvuor@jyu.fi) on 2024-06-05T06:18:04Z\nNo. of bitstreams: 0", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Made available in DSpace on 2024-06-05T06:18:04Z (GMT). No. of bitstreams: 0\n Previous issue date: 2024", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.format.extent", "value": "43", "language": "", "element": "format", "qualifier": "extent", "schema": "dc"}, {"key": "dc.language.iso", "value": "eng", "language": null, "element": "language", "qualifier": "iso", "schema": "dc"}, {"key": "dc.rights", "value": "In Copyright", "language": "en", "element": "rights", "qualifier": null, "schema": "dc"}, {"key": "dc.subject.other", "value": "Multiplex-immunohistochemistry", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "T-helper lymphocytes", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "tissue microarray", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.title", "value": "Composition and prognostic significance of T helper lymphocytes in lung cancer", "language": "", "element": "title", "qualifier": null, "schema": "dc"}, {"key": "dc.type", "value": "master thesis", "language": null, "element": "type", "qualifier": null, "schema": "dc"}, {"key": "dc.identifier.urn", "value": "URN:NBN:fi:jyu-202406054280", "language": null, "element": "identifier", "qualifier": "urn", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Master\u2019s thesis", "language": "en", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Pro gradu -tutkielma", "language": "fi", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Faculty of Sciences", "language": "en", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Matemaattis-luonnontieteellinen tiedekunta", "language": "fi", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Department of Biological and Environmental Science", "language": "en", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Bio- ja ymp\u00e4rist\u00f6tieteiden laitos", "language": "fi", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "University of Jyv\u00e4skyl\u00e4", "language": "en", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "Jyv\u00e4skyl\u00e4n yliopisto", "language": "fi", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Cell and molecular biology", "language": "en", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Solu- ja molekyylibiologia", "language": "fi", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "yvv.contractresearch.collaborator", "value": "public", "language": "", "element": "contractresearch", "qualifier": "collaborator", "schema": "yvv"}, {"key": "yvv.contractresearch.funding", "value": "4200", "language": "", "element": "contractresearch", "qualifier": "funding", "schema": "yvv"}, {"key": "yvv.contractresearch.initiative", "value": "student", "language": "", "element": "contractresearch", "qualifier": "initiative", "schema": "yvv"}, {"key": "dc.type.coar", "value": "http://purl.org/coar/resource_type/c_bdcc", "language": null, "element": "type", "qualifier": "coar", "schema": "dc"}, {"key": "dc.rights.accesslevel", "value": "openAccess", "language": null, "element": "rights", "qualifier": "accesslevel", "schema": "dc"}, {"key": "dc.type.publication", "value": "masterThesis", "language": null, "element": "type", "qualifier": "publication", "schema": "dc"}, {"key": "dc.subject.oppiainekoodi", "value": "4013", "language": null, "element": "subject", "qualifier": "oppiainekoodi", "schema": "dc"}, {"key": "dc.subject.yso", "value": "sy\u00f6p\u00e4taudit", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "keuhkosy\u00f6p\u00e4", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immunologia", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "lymfosyytit", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immunohistokemia", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immuunij\u00e4rjestelm\u00e4", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "cancerous diseases", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "pulmonary cancer", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immunology", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "lymphocytes", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immunohistochemistry", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immune system", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.rights.url", "value": "https://rightsstatements.org/page/InC/1.0/", "language": null, "element": "rights", "qualifier": "url", "schema": "dc"}]
|